Rational design of phenothiazinium derivatives and photoantimicrobial drug discovery

Mark Wainwright, Andrew McLean

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)
119 Downloads (Pure)

Abstract

While the model for conventional antimicrobial drug discovery is based securely on singular modes and sites of action, those associated with phenothiazinium photoantimicrobial candidates are both multifactorial and variable, resulting from oxidation events due to reactive oxygen species (ROS). The effective counteraction of such species and their variable targets is clearly problematic from the point of view of microbial resistance mechanism development, and offers considerable opportunity for the use of these agents in local infection control. However, this also means that drug development cannot be carried out using similar methods to those employed for conventional agents. Furthermore, these multifactorial photoantimicrobial agents are truly broad-spectrum since they are active against bacteria, fungi, viruses and protozoa, again at variance with the targeting of conventional, single-class antimicrobials.

This review concentrates on the use of the phenothiazinium class as exemplar photoantimicrobials, due to their pre-eminence in the field and considers the various criteria required for successful activity against microbes. These include alicyclic fusion, chalcogen substitution, benzo[a] fusion and the heavy atom effect, to decrease aggregation, improve ROS production and extend absorption wavelength, as well as conventional approaches, such as increasing cationic character to improve microbial selectivity/targeting.
Original languageEnglish
Pages (from-to)590-600
Number of pages11
JournalDyes and Pigments
Volume136
Early online date9 Sep 2016
DOIs
Publication statusPublished - 31 Jan 2017

Keywords

  • Drug resistance
  • Methylene blue
  • Phenothiazinium
  • Photoantimicrobial
  • Photosensitiser design

Fingerprint

Dive into the research topics of 'Rational design of phenothiazinium derivatives and photoantimicrobial drug discovery'. Together they form a unique fingerprint.

Cite this